COMMUNIQUÉS West-GlobeNewswire

AB Science fait un point sur la renégociation des modalités de remboursement de ses emprunts avec ses créanciers financiers
30/06/2025
COMMUNIQUE DE PRESSE AB SCIENCE FAIT UN POINT SUR LA RENEGOCIATION DES MODALITES DE REMBOURSEMENT DE SES EMPRUNTS AVEC SES CREANCIERS FINANCIERS UN ACCORD DE PRINCIPE A ETE OBTENU SUR UN DECALAGE DE DEUX ANS DU [...]
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors
30/06/2025
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE RENEGOTIATION OF LOAN REPAYMENT TERMS WITH ITS FINANCIAL CREDITORS AGREEMENT IN PRINCIPLE HAS BEEN REACHED ON A TWO-YEAR DEFERRAL OF REPAYMENT OF STATE-GUARANTEED LOANS [...]
Rakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025
30/06/2025
VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies [...]
Le groupe Affidea choisit b-rayZ comme partenaire d’IA privilégié en imagerie mammaire, marquant ainsi le début d’une collaboration stratégique
30/06/2025
LA HAYE, Pays-Bas, 30 juin 2025 (GLOBE NEWSWIRE) -- Dans une démarche stratégique visant à améliorer les résultats des patientes atteintes d’un cancer du sein, Affidea , l’un des principaux prestataires paneuropéens de [...]
Affidea Group selects b-rayZ as its preferred AI partner in breast imaging, marking strategic collaboration
30/06/2025
THE HAGUE, The Netherlands, June 30, 2025 (GLOBE NEWSWIRE) -- In a strategic move to improve patient outcomes in breast cancer, Affidea , a leading pan-European provider of community-based polyclinics, specialist [...]
HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy
30/06/2025
— Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy — — The only all-oral combination treatment option for these patients [...]
A factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform validated for the first time in humans
30/06/2025
Ad hoc announcement pursuant to Art. 53 LR Potential first-ever vaccine directed against C. difficile bacteria and spores induces positive antigen titers in humans that recognize the bacteria Initial data from healthy [...]
Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs
30/06/2025
Press Release Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs Geneva, Switzerland – June 30, 2025 – STALICLA SA, a Geneva-based [...]
Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders
30/06/2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – Addex Therapeutics (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule [...]
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
30/06/2025
Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy measures Advancing [...]
Changes to the Roche Enlarged Corporate Executive Committee
30/06/2025
Basel, 30 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Johannes (Hans) Clevers (1957), M.D., Ph.D., Head of Roche Pharma Research and Early Development (pRED) and member of the enlarged Corporate [...]
Communiqué de presse : Le riliprubart obtient la désignation de médicament orphelin au Japon pour la polyneuropathie inflammatoire démyélinisante chronique
30/06/2025
Le riliprubart obtient la désignation de médicament orphelin au Japon pour la polyneuropathie inflammatoire démyélinisante chronique Deux études de phase 3 sont actuellement en cours pour tester le riliprubart chez les [...]
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
30/06/2025
Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a potential first-in-class [...]
Nicox annonce que le dernier patient a terminé l’essai clinique de Phase 3 Denali sur NCX 470
30/06/2025
Communiqué de presse Nicox annonce que le dernier patient a terminé l’essai clinique de Phase 3 Denali sur NCX 470 Les premiers résultats sont attendus entre mi-août et mi-septembre 2025 L’autorisation de mise sur le [...]
Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial
30/06/2025
Press Release Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Results expected mid-August to mid-September 2025 New Drug Application (NDA) submission in the U.S. targeted for H1 2026 [...]
Communiqué de presse : Mise en ligne du document «Q2 2025 Aide mémoire »
30/06/2025
Mise en ligne du document «Q2 2025 Aide mémoire » Paris, France, le 30 juin 2025 . Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q2 2025 Aide mémoire [...]
Press release: Availability of the Q2 2025 Aide mémoire
30/06/2025
Availability of the Q2 2025 Aide mémoire Paris, France – June 30, 2025 . Sanofi announced today that its Q2 2025 Aide mémoire is available on the "Investors" page of the company's website: Second quarter 2025 (sanofi. [...]
SAFE - Informations complémentaires concernant le report de publication des résultats annuels 2024 - Suspension de la cotation de l’action Safe par Euronext à compter du 1er juillet 2025
30/06/2025
Informations complémentaires concernant le report de publication des résultats annuels 2024 Suspension de la cotation de l’action Safe par Euronext à compter du 1 er juillet 2025 Fleurieux-sur-l’Arbresle – France – 30 [...]
Global Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair
29/06/2025
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces it will once again support select players during high profile matches at The Championships, Wimbledon in 2025. The world’s oldest and [...]

Pages